POLBF (Poolbeg Pharma) ROE % Adjusted to Book Value: -27.19% (As of Dec. 2025)


What is Poolbeg Pharma ROE % Adjusted to Book Value?

Poolbeg Pharma POLBF -20.36% ROE % Adjusted to Book Value is -27.19% as of Dec. 2025. The stock has 1 warning sign investors should review.

Poolbeg Pharma's ROE % for the quarter that ended in Dec. 2025 was -67.98%. Poolbeg Pharma's PB Ratio for the quarter that ended in Dec. 2025 was 2.50. Poolbeg Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -27.19%.

Poolbeg Pharma ROE % Adjusted to Book Value Related Terms

Poolbeg Pharma ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Poolbeg Pharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poolbeg Pharma ROE % Adjusted to Book Value Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 -13.46 -7.88 -9.51 -26.25

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only -8.81 -6.16 -12.63 -23.14 -27.19

POLBF vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Poolbeg Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poolbeg Pharma ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Poolbeg Pharma's ROE % Adjusted to Book Value falls into.


Poolbeg Pharma ROE % Adjusted to Book Value Calculation

Poolbeg Pharma's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-65.62% / 2.50
=-26.25%

Poolbeg Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-67.98% / 2.50
=-27.19%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -27.19% mean?
Poolbeg Pharma (POLBF) has a ROE % Adjusted to Book Value of -27.19% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Poolbeg Pharma and its competitors.
Is Poolbeg Pharma's ROE % Adjusted to Book Value too high?
Poolbeg Pharma's current ROE % Adjusted to Book Value is -27.19%.
How does Poolbeg Pharma's ROE % Adjusted to Book Value compare to VRTX and REGN?
Poolbeg Pharma's ROE % Adjusted to Book Value of -27.19% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Poolbeg Pharma and its competitors. Poolbeg Pharma's current ROE % Adjusted to Book Value is -27.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current ROE % Adjusted to Book Value of -27.19%. The current ROE % Adjusted to Book Value is -27.19%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current ROE % Adjusted to Book Value is -27.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poolbeg Pharma Business Description

Other Exchanges POLB:UK7JN:Germany
Address 20 St. Andrew Street, The Clubhouse Holborn, London, GBR, EC4A 3AG
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.